A randomised, double-blind, placebo-controlled ascending dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations

Carl Clarke; JA Cooper; TAH Holdich

doi:10.1097/00002826-200105000-00003

A randomised, double-blind, placebo-controlled ascending dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations

Carl Clarke, JA Cooper, TAH Holdich

Research output: Contribution to journal › Article

22 Citations (Scopus)

Original language	English
Pages (from-to)	133-138
Number of pages	6
Journal	Clinical Neuropharmacology
Volume	24
DOIs	https://doi.org/10.1097/00002826-200105000-00003
Publication status	Published - 1 May 2001

Access to Document

10.1097/00002826-200105000-00003

Cite this

@article{b3c14869837c4993a4602eaf714f315b,

title = "A randomised, double-blind, placebo-controlled ascending dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations",

author = "Carl Clarke and JA Cooper and TAH Holdich",

year = "2001",

month = may,

day = "1",

doi = "10.1097/00002826-200105000-00003",

language = "English",

volume = "24",

pages = "133--138",

journal = "Clinical Neuropharmacology",

publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - A randomised, double-blind, placebo-controlled ascending dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations

AU - Clarke, Carl

AU - Cooper, JA

AU - Holdich, TAH

PY - 2001/5/1

Y1 - 2001/5/1

UR - http://www.scopus.com/inward/record.url?scp=0034977386&partnerID=8YFLogxK

U2 - 10.1097/00002826-200105000-00003

DO - 10.1097/00002826-200105000-00003

M3 - Article

C2 - 11391123

VL - 24

SP - 133

EP - 138

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

ER -